Systemic Inflammation in Liver Cirrhosis (SILC)

Sun Yat-sen University

Status: Completed

Conditions: Liver Cirrhosis

Study type: Observational

Funder types: Other

Identifiers

NCT04850534

SILC

Details and patient eligibility

About

Investigate systemic inflammation in liver cirrhosis patients

Enrollment: 400 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Decompensated liver cirrhosis, with endoscopy-verified high-risk esophagogastric varices;
2. Adult patients aged 18-75 years;
3. Willing to anticipate and informed consent form obtained

Exclusion criteria

1. History of prior radio-interventional therapy (TIPS or BRTO), liver transplantation, splenectomy, or hepatectomy;
2. Non-sinusoidal cirrhosis (e.g. vascular cirrhosis);
3. Coexistence with advanced hepatocellular carcinoma or other malignancies;
4. Coexistence with severe systemic diseases and less than 3 months of expected survival time;
5. Acute infection within 4 weeks before recruitment;
6. Antibiotic use within 4 weeks before recruitment;
7. Initial antiviral therapy for HBV or HCV within 4 weeks before recruitment;
8. Pregnant or lactating women;
9. Patients resistant to long-term follow-up

Trial design

400 participants in 2 patient groups

EGD+NSBB

Description:

Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices

EGD

Description:

Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices